[Form 4] COLGATE PALMOLIVE CO Insider Trading Activity

Rhea-AI Filing Summary

Colgate-Palmolive officer Hazlin John reported equity awards granted on 09/11/2025. The filing shows a grant of 4,045 restricted stock units (RSUs) and a stock option award covering 28,007 shares with an exercise price of $84.06. Following the RSU grant, Ms. John directly beneficially owns 18,455 shares and indirectly holds 5,382 shares through the issuer's 401(k) plan trustee.

The stock option vests in equal annual installments over three years beginning on 09/11/2026 and expires on 09/11/2033. The RSUs vest in three equal one-year installments starting on the grant date.

Positive

• 4,045 RSUs granted to the reporting officer on 09/11/2025
• 28,007 stock options granted with an exercise price of $84.06
• Clear vesting schedules: RSUs vest in three equal annual installments; options vest in equal annual installments over three years beginning one year after grant

Negative

• Potential dilution of up to 28,007 shares upon option exercise
• No cash price received for RSUs (grant recorded at $0.00) which increases outstanding share-based obligations

Insights

Securities Analyst

TL;DR: Routine executive equity grants reported: RSUs and multi-year options at $84.06, standard vesting schedule, no disposals.

The Form 4 documents a standard incentive compensation grant to an officer of Colgate-Palmolive. The awards comprise 4,045 restricted stock units vesting over three years and a stock option for 28,007 shares exercisable over three years after the first anniversary and expiring in 2033, with an exercise price of $84.06. There are no reported sales or other dispositions. For investors, this is a routine disclosure of executive compensation and does not, by itself, provide performance guidance or indicate changes in control.

Corporate Governance Expert

TL;DR: Governance-standard equity compensation awarded to a named officer with multi-year vesting and customary exercise terms.

The filing shows customary long-term incentive structures: time-based RSUs and stock options with a multi-year vesting schedule and an eight-year option term from grant. The reporting person is identified as Chief Growth Officer, and ownership totals after the grant are disclosed: 18,455 shares direct and 5,382 indirect via the 401(k) trustee. The document is a routine Section 16 disclosure consistent with regulatory requirements for officer awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hazlin John

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Growth Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		A(1)		4,045	A	$0.0000	18,455	D
Common Stock								5,382	I	By Issuer's 401(k) Plan Trustee

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$84.06	09/11/2025		A(2)		28,007		(3)	09/11/2033	Common Stock	28,007	$0.0000	28,007	D

Explanation of Responses:

1. Restricted stock unit award granted under the issuer's incentive compensation plan. The restricted stock unit award vests in equal 1/3 installments on each of the first, second and third anniversary of the date of grant.

2. Stock option award granted under the issuer's incentive compensation plan.

3. Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the September 11, 2025 grant date.

	/s/ Kristine Hutchinson, Attorney-in-Fact	09/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Hazlin John report for CL on 09/11/2025?

The Form 4 reports a grant of 4,045 restricted stock units and a 28,007-share stock option with an exercise price of $84.06.

What are the vesting and expiration terms of the stock option reported on CL Form 4?

The option vests in equal annual installments over three years beginning on 09/11/2026 and expires on 09/11/2033.

How many shares does Hazlin John beneficially own after the reported transaction?

Following the reported grant, the filing shows 18,455 shares beneficially owned directly and 5,382 indirectly via the issuer's 401(k) plan trustee.

Was any cash consideration paid for the RSUs reported by CL?

The filing records the RSU grant price as $0.0000, indicating no cash paid for the restricted stock unit award.

Does the Form 4 show any sales or dispositions by the reporting person?

No. The transactions reported on 09/11/2025 are acquisitions (grants); there are no disposals listed.